BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery, Is The Stock Still Undervalued?
BioCryst Pharmaceuticals (BCRX) is restructuring its research model by ceasing internal discovery programs and focusing on externally sourced rare disease projects. Despite a challenging long-term shareholder return, recent stock performance shows momentum. The company is considered undervalued with a fair value of $21.30 against its current trading price of $9.84, driven by the strong revenue growth of ORLADEYO, though investors should consider risks like reliance on this drug and early-stage pipeline uncertainties.
BCRX - Biocryst Pharmaceuticals Inc Volatility & Greeks
This article provides a comprehensive overview of BioCryst Pharmaceuticals Inc. (BCRX), detailing its recent stock performance, key financial metrics, volatility indicators, and various valuation ratios. It covers aspects from market capitalization and sales to insider ownership and analyst recommendations, offering a snapshot of the company's current financial health and market position.
If You Invested $1,000 in Biocryst Pharmaceuticals Inc (BCRX)
This article examines the historical returns of investing $1,000 in Biocryst Pharmaceuticals Inc (BCRX) over 1, 5, and 10 years, noting a 12.3% total return in the last year and a 235.8% return over ten years. It provides annual performance data for BCRX against the S&P 500 and a detailed company overview including its focus on hereditary angioedema (HAE) treatments, commercialized product ORLADEYO, pipeline, strategic transactions, and financial outlook. The article also addresses key risks and corporate governance changes.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted stock options and restricted stock units (RSUs) to nine newly-hired employees. These grants, totaling 33,950 stock options and 91,750 RSUs, were made on July 1, 2026, as inducements in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.65 per share and both options and RSUs vest over four years.
How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story
BioCryst Pharmaceuticals is discontinuing its internal discovery programs and closing its Birmingham Discovery Center, shifting its focus to externally sourced innovation for its rare disease pipeline. This move redefines the company's investment narrative, emphasizing execution risk around partnerships, capital allocation, and a credible path to future products, especially as its R&D model changes. The decision prompts investors to reconsider how future catalysts weigh against existing risks, with analysts projecting varied outcomes for revenue and profitability.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that its compensation committee granted stock options and restricted stock units (RSUs) to nine newly-hired employees. These grants, totaling 33,950 stock options and 91,750 RSUs, were made on July 1, 2026, as inducements for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants typically vest over four years, subject to continued service.
BioCryst lures 9 new hires with stock awards tied to $9.65 shares
BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted equity awards to nine new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards, granted on July 1, 2026, include stock options for 33,950 shares and Restricted Stock Units (RSUs) for 91,750 shares, with an exercise price of $9.65 per share equal to the closing price on the grant date. These options and RSUs will vest in four equal annual installments starting one year from the grant date, subject to continued service.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted stock options and restricted stock units (RSUs) to nine new employees. These inducements, totaling 33,950 stock options and 91,750 RSUs, were granted on July 1, 2026, as a material incentive for their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The grants vest in four equal annual installments and are subject to continued service.
How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story
BioCryst Pharmaceuticals is discontinuing its internal discovery programs and closing its Alabama Discovery Center by the end of 2026, shifting entirely to externally sourced innovation for its rare disease pipeline. This strategic pivot means the company will focus on execution risk associated with partnering, capital allocation, and maintaining a credible path to future products, especially as it manages competitive pressures and financial considerations. While existing revenue projections remain, external innovation and clinical progress for navenibart become critical factors for investors.
How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story
BioCryst Pharmaceuticals is discontinuing its internal discovery programs and closing its Birmingham Discovery Center by the end of 2026, pivoting to externally sourced innovation for its rare disease pipeline. This strategic shift will focus the company's investment narrative on external partnerships, capital allocation, and the clinical progress of navenibart, highlighting a transition period where disciplined spending and external innovation will be crucial for investor confidence. While near-term focus remains on ORLADEYO, this move changes how investors will weigh future catalysts against existing risks, with revenue projections of $930.1 million and earnings of $131.3 million by 2029.
BioCryst Pharmaceuticals Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
HC Wainwright & Co. has maintained its price target for BioCryst Pharmaceuticals (BCRX) at $32.00 per share. This indicates a continued positive outlook from the firm regarding the company's stock valuation. The unchanged price target suggests confidence in the company's performance or future prospects.
BioCryst to Close Birmingham Research Facility by End of 2026
BioCryst Pharmaceuticals announced it will close its Discovery Center of Excellence in Birmingham by the end of 2026. This strategic move aims to shift the company away from internal drug discovery, focusing instead on external partnerships for developing rare disease treatments. The biotechnology company seeks a more agile and cost-efficient approach to expand its pipeline, though the number of affected employees was not disclosed.
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – BX:BO1
This article provides limited financial information for BioCryst Pharmaceuticals, Inc. (BX:BO1), specifically noting its enterprise value to revenue forward. The content is primarily a placeholder or incomplete financial data point from TradingView, indicating market data and a future financial metric for the company.
BioCryst to close Alabama research facility, cut costs By Investing.com
BioCryst Pharmaceuticals announced it would close its Discovery Center of Excellence facility in Birmingham, Alabama by the end of 2026 and discontinue internal discovery programs. The company plans to shift its focus to external innovation and partnerships to build its rare disease pipeline, aiming for a more agile approach to research. This strategic move is expected to reduce non-GAAP operating expenses for 2026, while revenue guidance remains reaffirmed.
BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub
BioCryst Pharmaceuticals is shifting its research strategy by discontinuing internal discovery programs and closing its Birmingham, Alabama R&D facility by the end of 2026. This move is expected to lower 2026 non-GAAP operating expenses to $420–$440 million, while the company reaffirms its 2026 revenue guidance for ORLADEYO and total company sales. BioCryst will now focus on external innovation to build its rare disease pipeline and advance key clinical programs like navenibart and BCX17725.
BioCryst Sharpens Scientific Focus on External Innovation
BioCryst Pharmaceuticals announced a strategic shift to prioritize external innovation, discontinuing its internal discovery programs and closing its Birmingham research facility by the end of 2026. This move aims to accelerate rare disease pipeline growth through a more agile and capital-efficient approach. The company also updated its 2026 non-GAAP operating expense guidance, lowering it from $450-$470 million to $420-$440 million, and resolved a manufacturing delay for ORLADEYO oral pellets.
BCRX Forecast — Price Target — Prediction for 2027
This article provides a forecast for BioCryst Pharmaceuticals, Inc. (BCRX) stock, including analyst price targets, historical highs and lows, and upcoming earnings dates. It also details financial metrics such as earnings per share, revenue, net income, and EBITDA, along with employee count and dividend policy. The article states that analysts have a max estimate of $32.00 and a min estimate of $13.00 for BCRX's future price.
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX
This article mentions the enterprise value to revenue forward for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). It appears to be a stub or a placeholder from TradingView, providing financial data access without specific figures in the visible content. The article is part of a larger financial data and trading platform.
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Benchmark
BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX) has been removed from the Russell Small Cap Comp Value Benchmark, as reported by S&P Capital IQ. This news follows several other announcements, including BioCryst's decision to discontinue internal drug discovery programs and close its Birmingham facility to cut costs, and its removal from other Russell Value Benchmarks. The company, focused on rare diseases, recently presented new clinical data for its hereditary angioedema treatments.
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
BioCryst Pharmaceuticals announced a strategic shift to prioritize external innovation, discontinuing its internal discovery programs and closing its Birmingham, Alabama research facility by the end of 2026. This move aims to accelerate rare disease pipeline growth and improve capital efficiency. The company also completed enrollment for its Phase 3 ALPHA-ORBIT study for navenibart, resolved a manufacturing delay for ORLADEYO oral pellets, and updated its 2026 non-GAAP operating expense guidance to a lower range of $420-$440 million while reaffirming revenue guidance.
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
BioCryst Pharmaceuticals announced a strategic shift to prioritize external innovation by discontinuing internal discovery programs and closing its Birmingham research facility by the end of 2026. This move aims to build a sustainable rare disease pipeline more efficiently. The company also confirmed completing enrollment for its Phase 3 ALPHA-ORBIT study for navenibart, resolved a manufacturing delay for ORLADEYO oral pellets, and improved its 2026 non-GAAP operating expense guidance by $30 million.
Price to earnings forward of BioCryst Pharmaceuticals, Inc. – BX:BO1
The article focuses on the "Price to earnings forward" metric for BioCryst Pharmaceuticals, Inc. (BX:BO1), specifically mentioning its availability on TradingView. It provides metadata about the company's stock, market status, and data sources, but does not present any specific financial figures for the P/E forward ratio itself.
Price to sales forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX
The article discusses the forward price-to-sales ratio for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). It appears to be an entry from a financial data platform, providing a snapshot of a specific financial metric for the company.
Price to sales forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1
This article briefly presents the "Price to sales forward" financial metric for BioCryst Pharmaceuticals, Inc. (TRADEGATE:BO1) as displayed on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported for this specific financial data point.
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1
This article provides financial information for BioCryst Pharmaceuticals, Inc. (TRADEGATE:BO1), specifically focusing on its enterprise value to revenue forward metric. The content highlights the period, value, and change percentage of this financial indicator, noting that the data is provided by FactSet Research Systems Inc.
Price to book forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX
The article displays the "Price to book forward" metric for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) on TradingView. It provides a placeholder for the period, value, and change for this financial indicator but no actual data is presented. The content appears to be a stub or a section of a larger financial data page.
Enterprise value to EBIT forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1
This article provides the enterprise value to EBIT forward for BioCryst Pharmaceuticals, Inc. (TRADEGATE:BO1). The content appears to be a stub or a section from a financial data provider, displaying key financial metrics for the company.
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (DUS:BO1)
This article provides an overview of BioCryst Pharmaceuticals, Inc. (BO1) on the Dusseldorf Stock Exchange, detailing financial actuals and analyst estimates. It covers stock forecasts, historical price data, upcoming earnings reports, and recent financial performance including revenue and net income. The company's employee count and EBITDA are also mentioned.
BCRX Forecast — Price Target — Prediction for 2027
This article provides a forecast for BioCryst Pharmaceuticals, Inc. (BCRX) stock, detailing analyst price targets ranging from $13.00 to $32.00. It covers various financial metrics, historical performance, and responses to frequently asked questions about the company's stock, including current price, volatility, market capitalization, and upcoming earnings. The analysis concludes with a "strong buy" signal based on recent technical analysis.
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (SWB:BO1)
This article provides an overview of BioCryst Pharmaceuticals, Inc. (SWB:BO1) financials, including analyst price targets, historical stock data, and upcoming earnings reports. It details the company's past earnings and revenue figures, along with future estimates, and confirms that BioCryst Pharmaceuticals does not pay dividends. Key financial metrics like EBITDA and employee count are also discussed.
Biocryst Pharmaceuticals stock hits 52-week high at $10.32
BioCryst Pharmaceuticals Inc. (BCRX) stock reached a 52-week high of $10.32, with shares currently trading at $10.42. The company has seen significant momentum, surging 30% over the past six months and 28% year-to-date, despite an InvestingPro analysis indicating the stock is overvalued. Recent announcements include Q1 2026 earnings revealing an EPS miss but a revenue beat, and positive clinical data for its HAE therapies.
BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level
BioCryst Pharmaceuticals (BCRX) stock is experiencing its best week in over three months, with shares gaining for six straight sessions and up more than 33% in the past 10 sessions. This surge is driven by strong retail investor sentiment and positive news regarding its lead therapy, Orladeyo, which significantly reduced hereditary angioedema attacks in children and is projected to generate substantial revenue. Investors are closely watching a key resistance level around $10.32 to determine if the rally can be sustained.
Biocryst Pharmaceuticals stock hits 52-week high at $10.32 By Investing.com
BioCryst Pharmaceuticals (BCRX) stock hit a 52-week high of $10.32, currently trading at $10.42, marking a 30% surge over six months and 28% year-to-date. Despite being labeled overvalued by InvestingPro, the company holds a "GREAT" financial health score of 3.5. Recent developments include a Q1 2026 EPS miss but a revenue beat, positive clinical data for its HAE therapies, and increased options trading volume for BCRX.
Biocryst Pharmaceuticals stock hits 52-week high at $10.32 By Investing.com
BioCryst Pharmaceuticals (BCRX) stock reached a 52-week high of $10.32, with shares currently trading at $10.42, driven by a 30% surge in the past six months and 28% year-to-date. Despite an InvestingPro analysis suggesting the stock is overvalued, the company maintains a "GREAT" financial health score and recently reported a Q1 2026 revenue beat, though it missed EPS expectations. BioCryst also presented positive clinical data for its HAE therapy, ORLADEYO, and saw a significant increase in options trading volume.
BioCryst (BCRX) Is Up 11.7% After New HAE Data Spotlight ORLADEYO And Navenibart Potential
BioCryst Pharmaceuticals saw its stock rise 11.7% following the release of new clinical and real-world data for its hereditary angioedema (HAE) therapies, ORLADEYO and navenibart, at the EAACI Annual Meeting. The data reinforced ORLADEYO's long-term efficacy in reducing HAE attack burden and supported navenibart's progression to Phase 3 studies. While the new findings strengthen BioCryst's clinical narrative, the company's reliance on ORLADEYO for near-term revenue growth remains a key focus and risk for investors.
BioCryst Pharmaceuticals options trading jumps to 13,522
BioCryst Pharmaceuticals Inc. experienced a significant surge in options trading, with total contracts reaching 13,522 by midday in New York. The activity was predominantly in call options, with notable spreads identified for September 18, 2026, expiry dates at various strike prices. This article highlights the specific call and put volumes and the most traded options contracts.
BioCryst (BCRX) Is Up 11.7% After New HAE Data Spotlight ORLADEYO And Navenibart Potential
BioCryst Pharmaceuticals saw an 11.7% increase following the release of new clinical and real-world data for its hereditary angioedema (HAE) therapies, ORLADEYO and navenibart. The data, presented at the EAACI Annual Meeting, highlighted ORLADEYO's long-term efficacy in reducing HAE attacks and healthcare utilization, while navenibart's subgroup analyses supported its advancement to Phase 3. Despite these positive developments, the company's investment narrative remains heavily reliant on ORLADEYO's U.S. growth, with a single-product concentration presenting a significant risk.
BioCryst Pharmaceuticals Inc (BCRX) Financial Health: Profitability & Balance Sheet Analysis
BioCryst Pharmaceuticals Inc (BCRX) currently holds a financial score of 8.25, placing it 55th out of 389 in the Biotechnology & Medical Research industry, indicating stable financial health and high operating efficiency. The company recently reported a 7.48% year-over-year revenue increase to $156.41M, with an impressive 2255762.50% year-over-year surge in net profit. However, specific detailed data for various financial health dimensions like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company.
Trading Systems Reacting to (BCRX) Volatility
This article analyzes BioCryst Pharmaceuticals Inc. (BCRX) using AI models, identifying a near-term strong sentiment but a neutral mid and long-term outlook. It highlights an exceptional risk-reward setup targeting a 17.0% gain versus a 0.2% risk, and provides specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
BioCryst Pharmaceuticals Inc (BCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
BioCryst Pharmaceuticals Inc (BCRX) has an earnings forecast score of 8.60, ranking 97th in its industry. Analysts have set an average price target of $21.00 for BCRX, with most recommending a "Buy" rating. The company's expected revenue for the next quarter is $184.89M, and the EPS for the previous quarter was $1.17, with an expectation of $0.14 for the coming quarter.
BioCryst Pharmaceuticals Inc
This article provides a revenue breakdown for BioCryst Pharmaceuticals Inc (BCRX), detailing its market capitalization, current stock price, and P/E ratio. It highlights that the company has not yet disclosed relevant data for fiscal year 2025 by quarter or for fiscal years 2023 and 2024. The revenue contribution by region shows that the United States accounts for the vast majority of its revenue.
BioCryst Pharmaceuticals Inc (BCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of BioCryst Pharmaceuticals Inc (BCRX) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and lists "No Data" for both dividend payments and stock splits, indicating a lack of such historical events. The page also includes current stock performance metrics and market capitalization for BCRX.
Biocryst (BCRX) grants Theresa Heggie RSUs and stock options as board pay
BioCryst Pharmaceuticals director Theresa Heggie received equity awards, including 15,294 Restricted Stock Units and an automatic stock option grant for 33,540 shares, as part of her non-employee director compensation. The RSUs will vest on the first anniversary of the grant date, and the stock options have an exercise price of $8.50 per share, expiring in 2036. Following these awards, Heggie directly holds 80,646 shares of Common Stock.
BioCryst (BCRX) Stock After New HAE Data Presentation Is The Undervaluation Story Still Intact
BioCryst Pharmaceuticals (BCRX) garnered investor attention following new clinical data on its hereditary angioedema therapies, ORLADEYO and navenibart, presented at a recent European medical meeting. Despite a short-term stock price increase of 4.14% and a 20.80% year-to-date return, longer-term performance remains mixed, with 1-year and 5-year returns down. The company is currently loss-making but trading at a significant discount to analyst targets and intrinsic value estimates, suggesting it may be an undervalued opportunity if ORLADEYO maintains its strength against competition and pipeline programs avoid setbacks.
BioCryst (BCRX) director Vincent Milano receives stock and option grants
BioCryst Pharmaceuticals director Vincent Milano received equity compensation awards, including 15,294 shares of Common Stock and a stock option for 33,540 shares with an exercise price of $8.50. These awards are part of the company's Non-Employee Director Compensation Policy, with the Restricted Stock Units vesting in one year and options expiring in 2036, significantly increasing his direct holdings to 108,483 shares. The transactions are not open-market trades but policy-based compensation.
BioCryst (BCRX) director receives stock units and options grants
BioCryst Pharmaceuticals director Jon P. Stonehouse received equity compensation, including 15,294 shares of Common Stock and an Automatic Stock Option for 33,540 shares with an exercise price of $8.50. These grants were part of his non-employee director compensation policy. Following these transactions, his direct holdings increased to 1,339,775 shares, and indirect holdings of 40,000 shares each were reported by two irrevocable trusts associated with his wife.
Biocryst (NASDAQ: BCRX) director receives stock units and options grant
BioCryst Pharmaceuticals director Amy E. McKee received equity compensation in the form of restricted stock units (RSUs) and stock options. She was granted 15,294 shares of common stock as RSUs, which will vest on the first anniversary of the grant date, and an automatic stock option for 33,540 shares with an exercise price of $8.50, exercisable until June 11, 2036. Following these grants, McKee directly holds 47,177 common shares.
BioCryst (BCRX) Stock After New HAE Data Presentation Is The Undervaluation Story Still Intact
BioCryst Pharmaceuticals (BCRX) garnered investor attention following new clinical and real-world data presentations for its hereditary angioedema (HAE) therapies, ORLADEYO and navenibart. Despite recent short-term stock momentum and a perceived undervaluation to analyst targets and intrinsic value estimates, the company remains loss-making, prompting questions about whether it is mispriced or if the market is anticipating future challenges. The narrative suggests a fair value of $21.30, with strong revenue growth for ORLADEYO driven by increasing prescriptions and retention, though this hinges on its resilience against competition and pipeline success.
How Investors Are Reacting To BioCryst (BCRX) Expanding Its HAE Prophylaxis Data Across Patient Groups
BioCryst Pharmaceuticals recently presented new data for its HAE prophylaxis treatments, ORLADEYO and investigational navenibart, at the EAACI 2026 meeting. The data shows sustained pediatric outcomes for ORLADEYO and subgroup consistency for navenibart, highlighting BioCryst's efforts to expand HAE prophylaxis across various patient groups. While this reinforces the company's franchise story, the investment narrative still hinges on ORLADEYO's sustained revenue and navenibart's evolution into a significant second pillar, with analysts holding diverse forecasts for future revenue and earnings.
Oral HAE drug reduces child attacks; new antibody data across patient subgroups
BioCryst Pharmaceuticals presented new clinical and real-world data at the 2026 EAACI meeting for its hereditary angioedema (HAE) portfolio. Results for ORLADEYO in children aged 2-12 years demonstrated significant reductions in HAE attack rates and healthcare usage over 48 weeks, with no major safety concerns. Additionally, investigational antibody navenibart showed consistent attack reductions across various patient subgroups, supporting its ongoing Phase 3 evaluation.
